Search Results - "Luo, Allison"

Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study by Mayer, Lloyd, Sandborn, William J, Stepanov, Yuriy, Geboes, Karel, Hardi, Robert, Yellin, Michael, Tao, Xiaolu, Xu, Li An, Salter-Cid, Luisa, Gujrathi, Sheila, Aranda, Richard, Luo, Allison Y

“…Interferon-γ-inducible protein-10 (IP-10 or CXCL10) plays a role in inflammatory cell migration and epithelial cell survival and migration. It is expressed in…”
Get more information

Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab by KAINE, Jeffrey L, KIVITZ, Alan J, BIRBARA, Charles, LUO, Allison Y

“…OBJECTIVE: This study compared the immunogenicity of influenza and pneumococcal vaccines in adult patients with rheumatoid arthritis (RA) receiving adalimumab…”
Get full text

Abatacept for Crohn's Disease and Ulcerative Colitis by Sandborn, William J, Colombel, Jean–Frederic, Sands, Bruce E, Rutgeerts, Paul, Targan, Stephan R, Panaccione, Remo, Bressler, Brian, Geboes, Karl, Schreiber, Stefan, Aranda, Richard, Gujrathi, Sheila, Luo, Allison, Peng, Yun, Salter–Cid, Luisa, Hanauer, Stephen B

“…Background & Aims The efficacy of abatacept, a selective costimulation modulator, in Crohn's disease (CD) and ulcerative colitis (UC) is unknown. Methods Four…”
Get full text

Su1772 EARLY CHANGE IN CDAI PREDICTS IMPROVED QUALITY OF LIFE AFTER 12-WEEK INDUCTION THERAPY WITH TULISOKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: A POST HOC ANALYSIS FROM APOLLO-CD by Siegel, Corey A., Kharrat, Houssam A., Yen, Mark, Lu, JD, Luo, Allison, DuVall, Aaron

Get full text

Su1774 RELATIONSHIP BETWEEN SYMPTOM RESOLUTION AND CLINICAL RESPONSES AFTER 12 WEEKS OF TREATMENT WITH TULISOKIBART IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST HOC ANALYSIS FROM ARTEMIS-UC by Ma, Christopher, Boland, Brigid, Leong, Rupert W., Horynski, Marek, Yen, Mark, Lu, JD, Luo, Allison

Get full text

Su1809 – A Comparision Study of Systemic Versus Targeted Intracecal Anti-TNFα Monoclonal Antibody in an Adoptive T-Cell Transfer Muine Model of Colitis by Lee, Shaoying N., Singh, Sharat, Luo, Allison, Sandborn, William J., Chuang, Emil, Jones, Mitchell L.

Get full text

Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease by Khanna, Reena, Zou, Guangyong, D'Haens, Geert, Rutgeerts, Paul, McDonald, J W D, Daperno, Marco, Feagan, Brian G, Sandborn, William J, Dubcenco, Elena, Stitt, Larry, Vandervoort, Margaret K, Donner, Allan, Luo, Allison, Levesque, Barrett G

“…The Crohn's Disease Endoscopic Index of Severity (CDEIS) and Simple Endoscopic Score for Crohn's Disease (SES-CD) are commonly used to assess Crohn's disease…”
Get more information

Tu1852 PHARMACOKINETICS AND PHARMACODYNAMICS OF OPL-002, A HIGHLY SELECTIVE S1P1R MODULATOR, IN HEALTHY ADULT VOLUNTEERS by Luo, Allison, Lester, Robert, Schwab, Robert, Ogilvie, Kathleen, Huyghe, MiRa, Mohan, Raju, Nuss, John, Sandborn, William J.

Get full text

Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis by Sands, Bruce E., Feagan, Brian G., Peyrin-Biroulet, Laurent, Danese, Silvio, Rubin, David T., Laurent, Olivier, Luo, Allison, Nguyen, Deanna D., Lu, Jiandong, Yen, Mark, Leszczyszyn, Jaroslaw, Kempiński, Radosław, McGovern, Dermot P.B., Ma, Christopher, Ritter, Timothy E., Targan, Stephan

“…In this phase 2 trial, tulisokibart (a tumor necrosis factor–like cytokine 1A monoclonal antibody) was more effective than placebo in inducing clinical…”
Get full text

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis by Yellin, Michael, Paliienko, Igor, Balanescu, Andra, Ter-Vartanian, Semen, Tseluyko, Vira, Xu, Li-An, Tao, Xiaolu, Cardarelli, Pina M., LeBlanc, Heidi, Nichol, Geoff, Ancuta, Codrina, Chirieac, Rodica, Luo, Allison

“…Objective CXCL10 (also known as interferon‐γ–inducible 10‐kd protein [IP‐10]) is a chemokine that potentially plays a role in the immunopathogenesis of…”
Get full text

851 Targeted Intracecal anti-α4β7 Integrin Antibody Results in Reduce Accumulation of α4β7 Memory T-cells in Gut Tissue in DSS-induced Colitis Mice by Jones, Mitchell L., Lee, Shaoying N., Singh, Sharat, Luo, Allison, Sandborn, William J., Chuang, Emil, Wahl, Chris

“…INTRODUCTION: Systemically administered anti-α4β7 integrin antibodies such as Vedolizumab have been approved for the treatment of Crohn's disease and…”
Get full text

S1143 The Anti-TL1A Antibody PRA023 Demonstrated Proof-of-Concept in Crohn’s Disease: Phase 2a APOLLO-CD Study Results by Feagan, Brian G., Sands, Bruce E., Siegel, Corey A., Dubinsky, Marla C., Longman, Randy, Sabino, João, Laurent, Olivier, Luo, Allison, Lu, J. D., Nguyen, Deanna D., Towfic, Fadi, DuVall, Aaron, Woynarowski, Marek, Al Kharrat, Houssam, McGovern, Dermot

“…Methods: Key eligibility criteria included Crohn’s Disease Activity Index (CDAI) ≥220 and ≤450 with centrally read Simple Endoscopic Score (SES)-CD of ≥6 (≥4…”
Get full text

Su1875 – Development of Targeted Therapeutic Antibodies for the Treatment of Inflammatory Bowel Disease by Lee, Shaoying N., Singh, Sharat, Luo, Allison, Sandborn, William J., Wahl, Chris, Chuang, Emil, Jones, Mitchell L.

Get full text

Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial Program by WEINBLATT, Michael E, MORELAND, Larry W, HOCHBERG, Marc C, WESTHOVENS, Rene, COHEN, Roger B, KELLY, Sheila M, KHAN, Nader, PAPPU, Ramesh, DELAET, Ingrid, LUO, Allison, GUJRATHI, Sheila

“…To assess the overall safety, including rare events, of intravenous (IV) abatacept treatment in rheumatoid arthritis (RA). Data from 8 clinical trials of IV…”
Get full text

477a A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMISUC, COHORT 1 by Sands, Bruce E., Peyrin-Biroulet, Laurent, Danese, Silvio, Rubin, David T., Vermeire, Severine, Ma, Christopher, Ritter, Timothy, Panaccione, Remo, Feagan, Brian G., Mcgovern, Dermot P.B., Laurent, Olivier, Luo, Allison, Nguyen, Deanna D., Lu, JD, Wiechowska-Kozlowska, Anna, Leszczyszyn, Jaroslaw, Kempinski, Radoslaw, Kierkus, Jaroslaw, Targan, Stephan

Get full text

Eldelumab [anti-interferon-γ-inducible protein-10 antibody] Induction Therapy for Active Crohn's Disease: a Randomised, Double-blind, Placebo-controlled Phase IIa Study by Sandborn, William J, Rutgeerts, Paul, Colombel, Jean-Frédéric, Ghosh, Subrata, Petryka, Robert, Sands, Bruce E, Mitra, Pranab, Luo, Allison

“…This 11-week Phase IIa induction study evaluated the efficacy and safety of eldelumab in patients with active Crohn's disease. Adults with Crohn's Disease…”
Get full text

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study by Keystone, Edward Clark, Kremer, Joel M, Russell, Anthony, Box, Jane, Abud-Mendoza, Carlos, Elizondo, Mario Garza, Luo, Allison, Aranda, Richard, Delaet, Ingrid, Swanink, Rene, Gujrathi, Sheila, Luggen, Michael

“…To assess safety, immunogenicity and efficacy in rheumatoid arthritis (RA) patients switched from long-term intravenous to subcutaneous (SC) abatacept. In this…”
Get more information

Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study by Sandborn, William J., Colombel, Jean-Frédéric, Ghosh, Subrata, Sands, Bruce E., Dryden, Gerald, Hébuterne, Xavier, Leong, Rupert W., Bressler, Brian, Ullman, Thomas, Lakatos, Peter L., Reinisch, Walter, Xu, Li-An, Luo, Allison

“…Background and Aims: Interferon-γ-inducible protein-10 [IP-10] mediates immune cell trafficking from the circulation to the inflamed colon and decreases gut…”
Get full text

Use of the Endoscopic Healing Index (EHI) for Monitoring of Disease Activity in Crohn’s Disease Patients in the COVID Era by Abreu, Maria T, Okada, Lauren, Dervieux, Thierry, Luo, Allison, Jain, Anjali, Ritter, Timothy, Hanauer, Stephen B

“…Management of Crohn’s disease (CD) during COVID-19 is challenging when colonoscopy is not feasible. This study describes a blood-based test that has been…”
Get full text

Treatment patterns, complications, and disease relapse in a real-world population of patients with moderate-to-severe ulcerative colitis initiating immunomodulator therapy by Loftus, Jr, Edward V, Davis, Keith L, Wang, Chi-Chuan, Dastani, Homa, Luo, Allison

“…Immunomodulator (IM) treatments in ulcerative colitis (UC) are not curative and carry increased risk of complications, sometimes leading to therapy changes,…”
Get full text